OncoMatch/Clinical Trials/NCT06540729
RC48 in Combination With AK104 and Bevacizumab in OCCC
Is NCT06540729 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Disitamab vedotin in combination with AK104 and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer for ovary cancer.
Treatment: Disitamab vedotin in combination with AK104 and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer — Disitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer: a single-arm, phase II, multicenter study (DAB OCC study)
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: HER2 (ERBB2) IHC ≥1+ (IHC ≥1+)
HER2 IHC ≥1+.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immunotherapy (PD-1, PD-L1, CAR-T, CTLA-4)
Patients with a history of immunotherapy, including treatments targeting PD-1, PD-L1, CAR-T, and CTLA-4.
Lab requirements
Blood counts
white blood cell count ≥3.0×10^9/L, neutrophil count ≥1.5×10^9/L, platelet count ≥100×10^9/L, hemoglobin ≥80 g/L
Kidney function
creatinine ≤1.5× ULN
Liver function
AST ≤2.5× ULN, ALT ≤2.5× ULN, serum total bilirubin ≤1.5× ULN
Adequate bone marrow reserve function necessitates pre-operative blood routine parameters meeting specific criteria: white blood cell count ≥3.0×10^9/L, neutrophil count ≥1.5×10^9/L, platelet count ≥100×10^9/L, and hemoglobin ≥80 g/L. Satisfactory organ function entails biochemical test results within defined limits: AST ≤2.5× upper limit of normal (ULN), ALT ≤2.5× ULN, serum total bilirubin ≤1.5× ULN, and creatinine ≤1.5× ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify